Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CX-2009 |
| Trade Name | |
| Synonyms | CX2009|CX 2009|praluzatamab ravtansine |
| Drug Descriptions |
CX-2009 (praluzatamab ravtansine) is a probody drug conjugate consisting of the cytotoxic agent, maytansinoid DM4, and an antibody to the tumor associate antigen, CD166 (ALCAM), with a masking peptide that is cleaved by proteases specific to tumor cells (PMID: 32483421). |
| DrugClasses | |
| CAS Registry Number | 2145115-85-9 |
| NCIT ID | C134697 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CX-072 + CX-2009 | CX-072 CX-2009 | 0 | 1 |
| CX-2009 | CX-2009 | 0 | 2 |